Statesville Dialysis Center Of Wake Forest University is a medicare approved dialysis facility center in Statesville, North Carolina and it has 27 dialysis stations. It is located in Iredell county at 627 Signal Hill Drive Ext, Statesville, NC, 28625. You can reach out to the office of Statesville Dialysis Center Of Wake Forest University at (704) 872-0148. This dialysis clinic is managed and/or owned by Wake Forest University. Statesville Dialysis Center Of Wake Forest University has the following ownership type - Non-Profit. It was first certified by medicare in December, 1986. The medicare id for this facility is 342527 and it accepts patients under medicare ESRD program.
Name | Statesville Dialysis Center Of Wake Forest University |
---|---|
Location | 627 Signal Hill Drive Ext, Statesville, North Carolina |
No. of Dialysis Stations | 27 |
Medicare ID | 342527 |
Managed By | Wake Forest University |
Ownership Type | Non-Profit |
Late Shifts | No |
627 Signal Hill Drive Ext, Statesville, North Carolina, 28625 | |
(704) 872-0148 | |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
NPI Number | 1548247588 |
Organization Name | Statesville Dialysis Center |
Doing Business As | Statesville Dialysis Center Of Wake Forest University |
Address | 627 Signal Hill Drive Ext Statesville, North Carolina, 28625 |
Phone Number | (704) 872-0148 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 59% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 18% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 23% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 55% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 14% |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 57% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 22% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 21% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 57% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 34% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 79% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 21% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 64% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 12% |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
Dialysis patients with Hemoglobin data | 60 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 10 |
Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 2 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 86 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 759 |
Percentage of adult patients getting regular hemodialysis at the center | 98 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
Adult patients getting regular peritoneal dialysis at the center | 33 |
Adult patient months included in Kt/V greater than or equal to 1.7 | 237 |
Percentage of adult patients getting regular peritoneal dialysis at the center | 93 |
Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Statesville Dialysis Center Of Wake Forest University with elevated calcium levels.
Patients with hypercalcemia | 125 |
Hypercalcemia patient months | 1051 |
Patients with Serumphosphor | 129 |
Patients with Serumphosphor less than 3.5 mg/dL | 17 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 86 |
Patient months included in arterial venous fistula and catheter summaries | 647 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 76 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 12 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 101 |
Hospitalization Rate in facility | 181.3 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 299.2 |
Hospitalization Rate: Lower Confidence Limit | 118.5 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
The rate of readmission show you whether patients who were being treated regularly at Statesville Dialysis Center Of Wake Forest University were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 17.5 (As Expected) |
Readmission Rate: Upper Confidence Limit | 24.1 |
Readmission Rate: Lower Confidence Limit | 12 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Statesville Dialysis Center Of Wake Forest University get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .86 (As Expected) |
SIR: Upper Confidence Limit | 1.91 |
SIR: Lower Confidence Limit | .32 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Statesville Dialysis Center Of Wake Forest University's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 88 |
Transfusion Rate in facility | 59.1 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 106.6 |
Transfusion Rate: Lower Confidence Limit | 35.3 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
The rate of mortality show you whether patients who were being treated regularly at Statesville Dialysis Center Of Wake Forest University lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 528 |
Mortality Rate in facility | 21.4 (As Expected) |
Mortality Rate: Upper Confidence Limit | 26.3 |
Mortality Rate: Lower Confidence Limit | 17.2 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago
Statesville Dialysis Center Of Wake Forest University Location: 627 Signal Hill Drive Ext, Statesville, North Carolina, 28625 Phone: (704) 872-0148 |
West Iredell Dialysis Center Location: 115 Westbrook Lane, Statesville, North Carolina, 28625 Phone: (704) 881-0336 |
News Archive
BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.
MedMira Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office for its rapid flow-through test (RFT) methodology, the technology platform its rapid tests are built on.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.
Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.
› Verified 7 days ago